AZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
AstraZeneca PLC (AZN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and hedge fund buying trends support a bullish outlook. While technical indicators are mixed, the long-term growth potential and analyst optimism outweigh short-term fluctuations.
The MACD is negatively expanding (-2.127), indicating bearish momentum. RSI is neutral at 64.347, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 202.962, and resistance is at 211.068. The stock is trading near support levels, which may present a buying opportunity.
FDA approval for CALQUENCE combination therapy for chronic lymphocytic leukemia.
Positive results from the DESTINY-Breast05 trial and European Medicines Agency validation for ENHERTU.
Hedge funds are significantly increasing their positions in AstraZeneca (+166.61% buying activity).
Strong Q4 financial performance with revenue, net income, and EPS growth.
Deutsche Bank maintains a Sell rating on the stock despite raising the price target.
Gross margin declined YoY by -2.70%.
Mixed sentiment in the options market with a high put-call volume ratio.
In Q4 2025, AstraZeneca's revenue increased by 4.11% YoY to $15.503 billion. Net income surged by 55.07% YoY to $2.326 billion, and EPS grew by 55.21% YoY to $1.49. However, gross margin dropped by -2.70% YoY to 78.89%. Overall, the company demonstrated strong growth in profitability and earnings.
Analyst sentiment is mixed but leans positive. Citi and Berenberg have Buy ratings with price targets of 17,000 GBp and 160 GBp, respectively, citing strong mid-term growth potential and a robust pipeline. JPMorgan maintains an Overweight rating with a 16,000 GBp target and added AstraZeneca to its European Analyst Focus List. However, Deutsche Bank maintains a Sell rating despite raising its price target to 11,500 GBp.
